共 50 条
- [21] LUX-Lung: determining the best EGFR inhibitor in NSCLC? [J]. LANCET ONCOLOGY, 2015, 16 (02): : 118 - 119
- [23] Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial [J]. LANCET ONCOLOGY, 2012, 13 (05): : 539 - 548
- [24] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials [J]. LANCET ONCOLOGY, 2015, 16 (02): : 141 - 151
- [25] Not All RCTs Are Created Equal: Lessons From Early AIDS Trials [J]. AMERICAN JOURNAL OF BIOETHICS, 2015, 15 (04): : 45 - 47
- [26] LUX-Lung 7: is there enough data for a final conclusion? reply [J]. LANCET ONCOLOGY, 2016, 17 (07): : E268 - E269
- [29] Not All Risks Are Created Equal [J]. Bulletin of the Chinese Academy of Sciences, 2016, (04) : 256 - 256